• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RCT Results: Does Therapeutic Heparin Dose Improve Outcomes in Patients with COVID-19?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Thrombosis and inflammation may be a cause of poor COVID-19 outcomes, and therapeutic doses of anticoagulation may improve outcomes 
  • Investigators (ATTACC, ACTIV-4a, and REMAP-CAP Investigators; NEJM, 2021) sought to determine whether unfractionated or low-molecular-weight heparin improves outcomes in hospitalized patients  

METHODS: 

  • Open-label, adaptive, multiplatform, controlled trial 
    • Response-adaptive randomization allows for randomization probabilities to be modified as evidence about treatment effects are accrued  
  • Participants 
    • Non-critically ill arm 
      • Hospitalized COVID-19 patients who did not require critical care–level organ support at enrollment 
    • Critically ill arm 
      • Hospitalized COVID-19 patients with ICU-level respiratory or cardiovascular organ support 

Note: Patients were further subcategorized based on D-dimer levels 

  • Interventions 
    • Therapeutic dose anticoagulation with heparin 
    • Usual care pharmacologic thromboprophylaxis 
  • Primary outcome 
    • Organ support–free days 
      • Evaluated on an ordinal scale that combined in-hospital death  
    • Number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge 
      • Evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level 

RESULTS: 

Non-Critically Ill Patients 

  • 2219 patients  
  • Probability that heparin increased organ support–free days compared with usual-care thromboprophylaxis was 98.6% 
    • aOR 1.27 (95% Credible Interval [CrI], 1.03 to 1.58) 
  • The adjusted absolute between-group difference in survival until hospital discharge without organ support favored therapeutic-dose anticoagulation  
    • Usual-care group: 76.4% survived until hospital discharge  
    • Therapeutic-dose group: 80.2%  
    • 95% CrI, 0.5 to 7.2 
  • Probability of the superiority of heparin over usual-care thromboprophylaxis based on D-dimer levels 
    • High D-dimer cohort: 97.3% 
    • Low D-dimer cohort: 92.9% 
    • Unknown D-dimer cohort: 97.3% 
  • Major bleeding occurrences 
    • Therapeutic-dose group: 1.9% 
    • Usual care group: 0.9% 

Critically Ill Patients 

  • 1098 patients: 534 in heparin cohort | 564 in usual care 
  • Median organ support-free days 
    • Therapeutic-dose group: 1 day (IQR -1 to 16) 
    • Usual care group: 4 days (IQR -1 to 16) 
    • Adjusted proportional odds ratio 0.83 (95% CrI, 0.67 to 1.03) 
    • Posterior probability of futility (defined as an odds ratio <1.2), 99.9% 
  • The percentage of patients who survived to hospital discharge was similar in the two groups 
    • Heparin group: 62.7% 
    • Usual care group: 64.5% 
    • aOR 0.84 (95% CrI, 0.64 to 1.11) 
  • Major bleeding occurrences 
    • Heparin group: 3.8% 
    • Usual care group: 2.3% 

CONCLUSION: 

  • For non-critically ill hospitalized COVID-19 patients, therapeutic doses of heparin increased the probability of survival to hospital discharge, and reduced the number of days requiring cardiovascular or respiratory organ support 
    • Limitation of study: lack of detailed screening data and therefore reasons for trial exclusion were not available (other than risk for bleeding or other clinical indication for anticoagulation)  
    • More major bleeding complications were associated with the therapeutic dosing group  
  • For critically ill COVID-19 patients, heparin did not have an effect on survival to hospital discharge or number of days free of organ support 
  • An accompanying editorial concludes

…available evidence does not support use of therapeutic-dose heparin or LMWH for thrombosis prevention in critically ill patients 

In spite of the signals of benefit of anticoagulation in noncritically ill patients with Covid-19, physicians must deal with the key issues regarding the lack of insight into the mechanisms by which heparin or LMWH does (or does not) provide protection and the question of whether the individual patient’s bleeding risk outweighs the benefit 

Learn More – Primary Sources: 

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 

Editorial: Surviving Covid-19 with Heparin? 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Is Blood Viscosity Greater in Patients with Severe COVID-19?
Potential Pathology Behind AstraZeneca COVID-19 Vaccination and Blood Clots
Thrombotic Events and COVID-19: How Often do they Occur and What are the Risk Factors?
Is Anticoagulation Therapy in COVID-19 Patients Associated with Lower Mortality?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site